Document Detail


Postmenopausal hypertension: role of the Renin-Angiotensin system.
MedLine Citation:
PMID:  20679182     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
After menopause, blood pressure increases in women. However, the underlying mechanisms responsible for postmenopausal hypertension are not completely understood. This study was conducted to determine the role that the renin-angiotensin system (RAS) plays in post-menopausal hypertension. Post-estrous cycling (postmenopausal) spontaneously hypertensive rats or young female controls were treated with losartan, an angiotensin (Ang) II type 1 receptor blocker, for 25 days. Mean arterial pressure was recorded continuously by radiotelemetry. Losartan significantly decreased blood pressure in postmenopausal rats and young female controls but failed to normalize blood pressure in postmenopausal rats to levels found in young controls. Plasma renin activity and plasma angiotensinogen were significantly elevated, and intrarenal Ang II type 1 receptor and renin mRNA expression were significantly downregulated in postmenopausal rats. Therefore, RAS only partially contributes to hypertension in postcycling spontaneously hypertensive rats, whereas hypertension in young females is mediated mainly by the RAS. The data suggest that other mechanisms besides activation of the RAS are likely involved in postmenopausal hypertension.
Authors:
Licy L Yanes; Damian G Romero; Radu Iliescu; Huimin Zhang; Deborah Davis; Jane F Reckelhoff
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-08-02
Journal Detail:
Title:  Hypertension     Volume:  56     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-19     Completed Date:  2010-09-13     Revised Date:  2014-09-18    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  359-63     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Analysis of Variance
Angiotensin II Type 1 Receptor Blockers / pharmacology
Angiotensinogen / genetics,  metabolism
Animals
Blood Pressure / drug effects
Female
Hypertension / genetics,  metabolism,  physiopathology*
Kidney / drug effects,  metabolism,  physiopathology
Losartan / pharmacology*
Peptidyl-Dipeptidase A / genetics,  metabolism
Rats
Rats, Inbred SHR
Renin / genetics,  metabolism
Renin-Angiotensin System / drug effects,  physiology*
Reverse Transcriptase Polymerase Chain Reaction
Telemetry
Grant Support
ID/Acronym/Agency:
HL51971/HL/NHLBI NIH HHS; HL66072/HL/NHLBI NIH HHS; HL69194/HL/NHLBI NIH HHS; P01 HL051971/HL/NHLBI NIH HHS; P01 HL051971-165260/HL/NHLBI NIH HHS; R01 HL066072/HL/NHLBI NIH HHS; R01 HL066072-07/HL/NHLBI NIH HHS; R01 HL069194/HL/NHLBI NIH HHS; R01 HL069194-07W1/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 11002-13-4/Angiotensinogen; EC 3.4.15.1/Peptidyl-Dipeptidase A; EC 3.4.23.15/Renin; JMS50MPO89/Losartan
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously h...
Next Document:  Targeted Genomic Disruption of H-Ras Induces Hypotension Through a NO-cGMP-PKG Pathway-Dependent Mec...